Momentous Data For Oxford/Novavax Malaria Vaccine
First To Achieve WHO's 75% Efficacy Goal
A year to the day since the first dose of its COVID-19 vaccine was given, Oxford University's Jenner Institute has unveiled stellar findings from a Phase IIb trial of its malaria vaccine.
You may also be interested in...
GSK is transferring technology for the manufacture of its malaria vaccine antigen to Bharat Biotech and by 2029 will also transfer rights to supply the vaccine to WHO-approved immunization programs. The deal is expected to improve access via lower costs for such programs.
While Orphazyme's attempts to get approval for arimoclomol failed miserably, new owner KemPharm is confident it can get the oral heat shock protein amplifier across the regulatory finishing line for Neimann-Pick disease type C.
Big pharma players have embraced a tricky operating environment in 2022 so far, treading a tightrope with political and financial challenges impacting their decision making and threatening to blow them off balance. However, what is not in doubt is the healthy growth experienced by those companies based around mainland Europe and the UK.